Abstract: Amide derivatives represented by the formula (I): wherein: A is a cycloalkyl group, an aryl group or a heteroaryl group; X is a nitrogen atom or CR17; Y is —NRa—, —(CRbRb?)m-, and the like; m is 0 to 4; and R1 to R17 may be the same or different and each is a hydrogen atom, a halogen atom, a cyano group, a nitro group, a carboxyl group, a formyl group, a hydroxyl group, an ammonium group, an alkyl group optionally having one or more substituents, -ZR18 and the like, Z is —O—, —S(O)p-, —S(O)pO—, —NH—, —NR19-, and the like; or a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof may be applied to pharmaceutical use such as anti-inflammatory and analgesic action and the like.

Abstract: The invention is directed to bipyridine-based compound and organic light emitting diodes (OLED) including organic layers having the bipyridine-based compound. OLEDs including organic layers having the bipyridine-based compounds can have low driving voltages, high current densities, high efficiencies and long lifetimes.

Abstract: Compounds having the following generic formula are disclosed.

Abstract: The present invention relates to compounds, pharmaceutical compositions and methods which inhibit the binding of coactivator proteins in nuclear receptors, including estrogen receptors (alpha and/or beta), androgen receptors, thyroid receptors and peroxisome proliferators-activated receptors, among others. Compounds according to the present invention may be useful in the treatment of a variety of disease states or conditions which are mediated through nuclear receptors.

Abstract: A process for the preparation of Compound (I) comprising reacting Compound (II) with a base in an aprotic solvent, which is represented by the following scheme: wherein R1 and R2 are each independently lower alkyl.

Abstract: The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration.

Abstract: 4-pyridone derivatives of Formula (I) and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical formulations thereof and their use in chemotherapy of certain parasitic infections such as malaria, are provided.

Abstract: The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. In the formula, Q indicates NH, O or S; and R1, R2, R3, R4 and R5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C1-6 alkyl group or a group represented by the formula —X-A (wherein X indicates a single bond, an optionally substituted C1-6 alkylene group etc.; and A indicates an optionally substituted C6-14 aromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).

Abstract: The invention relates to compounds of formula IA and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof.

Abstract: The present invention relates to a compound and a group of compounds which are inhibitors of Rho kinase (ROK, ROCK). In addition, the invention relates to methods of treatment and use of the compounds in the manufacture of a medicament for application to a number of therapeutic indications including cardiovascular disease (coronary vasospasm, hypertensive disease, arteriosclerosis), stroke, cancer, erectile dysfunction, asthma, osteoporosis, glaucoma and AIDS. The compounds can be used in screening programmes against protein kinases. The invention also provides methods for making compounds and libraries that include these compounds.

Abstract: The present invention relates to substituted pyridine compounds of Formula (I) and derivatives thereof, and to a process for preparing these substituted pyridines. The invention also relates to the use of the substituted pyridines as intermediates in the production of pharmaceutical, chemical and agro-chemical products.

Abstract: A compound represented by the following Formula (1) is useful as an electron transport material of an organic EL device, and an organic EL device comprising the compound in the electron transport layer is long in life, and low in drive voltage: wherein G is an n-valent link, n is an integer of 2 to 4; R1 to R4 are each independently hydrogen, a monovalent group, or a free valency bonded with G, and R5 to R8 are each independently hydrogen or a monovalent group, and one of R1 to R4 is a free valency bonded with G; and n groups of 2,3?-bipyridyl may be the same or different with each other.

Abstract: The present invention concerns coloring keratin fibers, especially human hair, with colored metal complexes.

Abstract: The present invention provides a method of industrially and advantageously producing a 5-(2?-pyridyl)-2-pyridone derivative. The present invention relates to a production method of a 5-(2?-pyridyl)-2-pyridone derivative represented by the formula (VI), which includes reacting a pyridine derivative of the formula (I) with a brominating agent to give a 5-bromopyridine derivative of the formula (II), reacting the obtained 5-bromopyridine derivative with a metallizing agent to give an organometallic compound of the formula (III), reacting the obtained organometallic compound with a 2-sulfonylpyridine derivative of the formula (IV) to give a 6-alkoxy-3,2?-bipyridine derivative of the formula (V) and hydrolyzing the obtained 6-alkoxy-3,2?-bipyridine derivative: wherein each symbol is as defined in the Description.

Abstract: Methods and compositions to extract radionuclides such as various actinides and lanthanides from organic and/or aqueous solutions by utilizing extractant functionalized carbon nanotubes are disclosed. More particularly, phosphorous-containing (such as phosphine oxides, phosphoric acids or phosphates) organic extractants and other predesigned extractants (such as crown ethers, calncrown derivatives, malonamide and diglycolamide derivatives, polyethylene glycol derivatives, cobalt dicarbollite derivatives, and N-donating heterocyclic ligands) can be covalently and/or non-covalently employed on the surfaces and/or ends (tips) of carbon nanotubes for the purpose of removal radionuclides such as various actinides and lanthanides from organic and/or aqueous solutions. Extractant functionalized carbon nanotubes can be used for extracting radioactive nuclides from nuclear waste or spent nuclear fuel, which are produced and/or reprocessed from the nuclear power generation or other nuclear application.

Abstract: A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one characterized in having a diffraction peak at a diffraction angle (2?±0.2°) of 15.4° in a powder X-ray diffraction or others.

Abstract: Provided is a method of manufacturing a bipyridinium compound denoted by general formula (A). In general formula (A), Ar1 and Ar2 each independently denote an optionally substituted (hetero)aryl group, R3 and R4 each independently denote a substituent that may form a ring with a pyridine ring to which the substituent substitutes, m3 and m4 each independently denote an integer ranging from 0 to 4, X denotes a halogen atom or RSO3, and R denotes an optionally substituted aryl group or alkyl group. The method can manufacture a 4,4?-bipyridinium compound under mild reaction conditions in an integrated manner without separation of intermediates.

Abstract: Use of metal complex compounds of formula [LnMemXp]zYq??(1), wherein Me is manganese, titanium, iron, cobalt, nickel or copper, X is a coordinating or bridging radical, n and m are each independently of the other an integer having a value of from 1 to 8, p is an integer having a value of from 0 to 32, z is the charge of the metal complex, Y is a counter-ion, q=z/(charge Y), and L is a ligand of formula wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are each independently of the others hydrogen; unsubstituted or substituted C1-C18alkyl or aryl; cyano; halogen; nitro; —COOR12 or —SO3R12 wherein R12 is in each case hydrogen, a cation or unsubstituted or substituted C1-C18alkyl or aryl; —SR13, —SO2R13 or —OR13 wherein R13 is in each case hydrogen or unsubstituted or substituted C1-C18alkyl or aryl; —N(R13)—NR?13R?13 wherein R13, R?13 and R?13 are as defined above for R13; —NR14R15 or —N?R14R15R16 wherein R14, R15 and R16 are each independently of the other(s) hydrogen or unsubstituted or s

Abstract: The invention relates to a pyridine oxide compound represented by formula (I), an optically active compound thereof, a salt thereof and a hydrate thereof, and, in the presence of the compound as a catalyst, performing 1) a method for producing an ester compound or an amide compound from a carboxylic acid equivalent and an alcohol or an amine, 2) an asymmetric esterification reaction or 3) an asymmetric amidation reaction.

Abstract: An acid addition salt of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one or a hydrate thereof, wherein the acid is selected from the group consisting of benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, fumaric acid, tartaric acid, succinic acid and benzoic acid.

Abstract: An amorphous form of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridine-2-one.

Abstract: It is intended to provide novel labeling reagents characterized by having a group capable of binding to a substance to be labeled (for example, a biological substance, a physiologically active substance, etc.), easily forming a complex together with a rare earth ion, the complex being stable in an aqueous solution, and having a sufficient fluorescence intensity and a long fluorescence life time regardless of buffer types; complexes composed of the above labeling reagent with a rare earth ion; fluorescence labels containing the above complex; a fluorescence assay method using the above fluorescent label; etc. Namely, labeling reagents comprising a compound having a 2,2?:6?,2?-tripyridine skeleton or a 2,6-dipyrazolopyridine skeleton and having a group capable of binding to a substance to be labeled (for example, a biological substance, a physiologically active substance, etc.

Abstract: 4-pyridone derivatives of Formula (1) and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical formulations thereof and their use in chemotherapy of certain parasitic infections such as malaria, are provided.

Abstract: The present invention relates to compounds of formula (I) wherein A, B, Q, X, Y, R1, and R2 are as defined herein; pharmaceutical compositions containing them; a process for their manufacture; and methods for treating CNS disorders with the same.

Abstract: The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.

Abstract: The invention provides compounds of formula (I) wherein the substituents are as defined in the description, processes and intermediates for their preparation and their use as pharmaceuticals.

Abstract: Use of metal complex compounds of formula [LnMemXp]zYq, ??(1) wherein Me is manganese, titanium, iron, cobalt, nickel or copper, X is a coordinating or bridging radical, n and m are each independently of the other an integer having a value of from 1 to 8, p is an integer having a value of from 0 to 32, z is the charge of the metal complex, Y is a counter-ion, q=z/(charge Y), and L is a ligand of formula wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are each independently of the others hydrogen; unsubstituted or substituted C1-C18alkyl or aryl; cyano; halogen; nitro; —COOR12 or —SO3R12 wherein R12 is in each case hydrogen, a cation or unsubstituted or substituted C1-C18alkyl or aryl; —SR13, —SO2R13 or —OR13 wherein R13 is in each case hydrogen or unsubstituted or substituted C1-C18alkyl or aryl; —N(R13)—NR?13R?13 wherein R13, R?13 and R?13 are as defined above for R13; —NR14R15 or —N?R14R15R16 wherein R14, R15 and R16 are each independently of the other(s) hydrogen or unsubstituted or substi

Abstract: Pyrimidine compounds of general formula: wherein —R1 represents in which R11 is hydrogen, C1-6 alkyl, halogen, hydroxy, C1-12 alkoxy, nitro, amino, C1-6 alkylsulfonylamino, C1-6 alkoxycarbonyl, C1-6 alkylamino, di (C1-6 alkyl)amino, C1-6 alkanoylamino, phenyl C1-6 alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2 represents hydrogen or halogen; R3 represents hydrogen, —CR31R32R33; R4 is hydrogen, carbamoyl, CN, carboxyl, etc.; R5 is amino, C1-6 alkylamino, di C1-6 alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.

Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts, hydrates, solvates, geometrical isomers, tautomers, optical isomers, or prodrug forms thereof, wherein X, Y, Z, R1, R2, R3 and R4 are as defined herein are capable of binding to the active site of protein kinase enzymes. In particular, they are inhibitors of a serine/threonine kinase more particularly Rho kinase (ROK, ROCK).

Abstract: Disclosed herein is a class of tunable phenylacetylene compounds as well as compositions and methods for their use as host compounds for ligand binding. In certain examples the hosts report binding events by exhibiting altered spectroscopic properties, such as different fluorescent emission spectra.

Abstract: This invention relates to a group of novel chelating agents, novel chelates, biomolecules labeled with said chelates or chelating agents as well as solid supports conjugated with said chelates, chelating agents or labeled biomolecules. Especially the invention relates to novel chelating agents useful in solid phase synthesis of oligonucleotides or oligopeptides and the oligonucleotides and oligopeptides so obtained.

Abstract: The present invention relates to compounds of formula (I-VII) or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R6, R7 and R8 are defined herein. The present invention also relates to methods of treating pain using these compounds and pharmaceutical compositions including these compounds.

Abstract: The present invention provides an indene derivatives having a new structure and an organic light-emitting diode using the same. The organic light-emitting diode according to the present invention shows improved effects in efficiency, driving voltage and stability.

Abstract: Disclosed herein are a novel dye for a photoelectric device and a photoelectric device comprising the dye. More particularly, the dye for a photoelectric device incorporates different quaternary ammoniums into a carboxyl or phosphoric acid-substituted bipyridyl ligand of the dye, and a photoelectric device comprising the same. The dye for a photoelectric device as disclosed herein exhibits improved photosensitivity and light absorbing characteristics, thereby making it possible to fabricate a highly efficient photoelectric device when the dye is included in the device.

Abstract: Disclosed are new dihydropteridinones of general formula (I) wherein the groups R1 to R5, Ra to Rc, W, Q1 and Q2 have the meanings given in the claims and specification, the isomers thereof and the use thereof for preparing a pharmaceutical composition for the treatment of diseases characterised by excessive or abnormal cell proliferation.

Abstract: We describe substituted benzenesulfoximine compounds having anti-inflammatory activity, processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of inflammatory diseases.

Abstract: The present invention relates to compounds of formula (I-VII) or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R6, R7 and R8 are defined herein. The present invention also relates to methods of treating pain using these compounds and pharmaceutical compositions including these compounds.

Abstract: The invention relates to intermediate compounds of the formula wherein R1 is H or a protecting group, R2 and R3 each independently represent H, methyl, or a leaving group, provided that at least one, but not both, of R2 and R3 is a leaving group. The intermediate compounds are useful for the synthesis of discodermolide, its derivatives, and related compounds.

Abstract: The subject invention provides materials and methods for inhibiting the biofouling of surfaces exposed to aquatic environments. In one embodiment, the subject invention provides additives for marine paints and surface treatments. The subject invention further provides repellents and selective inhibitors for aquatic and/or terrestrial crustacean pests.

Abstract: The invention provides a bipyridine derivative useful as an intermediate for pharmaceutical products, agricultural chemicals, electrophotographic photosensitive materials, dyes and the like, which is a bipyridine derivative represented by the general formula (I) and a salt thereof: wherein R1 represents an alkyl group with 2 to 20 carbon atoms having a substituent, substituted or unsubstituted aminomethyl group, trifluoromethyl group, substituted or unsubstituted thiomethyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted alkoxy group, substituted or unsubstituted aryloxy group, substituted carbonyl group, substituted sulfonyl group, unsubstituted or monosubstituted carbamoyl group, unsubstituted or monosubstituted sulfamoyl group, substituted or unsubstituted thiol group, unsubstituted or monosubstituted amino group, substituted carbonylamino group, substituted or unsubstituted ureido group, nitro group, cyano group, formyl group or an equivalent thereof, iodine atom or flu

Abstract: The invention relates to intermediate compounds of the formula wherein R1 is H or a protecting group, R2 and R3 each independently represent H, methyl, or a leaving group, provided that at least one, but not both, of R2 and R3 is a leaving group. The intermediate compounds are useful for the synthesis of discodermolide, its derivatives, and related compounds.

Abstract: A chiral catalyst comprising a 3, 4-disubstituted pyridine, or a salt, N functionalised derivative, dimer or oligomer thereof, wherein the 3-substituent is substantially hindered from rotation about the bond (sp2-sp2 biaryl axis) linking it to pyridine and the 4-substituent is an aliphatic or aromatic amine linked by a single bond to the pyridine, the pyridine nitrogen being functionalised or unfunctionalised, preferably comprising a compound of formula I wherein Z is a group substantially hindered from rotation about its bond; and each of R1 and R2 are independently selected from C1-30 alkyl, C3-30 cyclo alkyl and/or C3-30 aryl, or NR1 R2 form a cyclic amine; wherein R1 and/or R2 may be optionally substituted and/or include one or more heteroatoms; a composition or support comprising the catalyst; process for the preparation and resolution thereof; process for stereoselective reaction of an optically inactive substrate using the catalyst; and the optically active reaction product thereof.

Abstract: Aminopyridine derivatives of the following formula I which exhibit pharmacological activity at estrogen receptors alpha (ER?) and beta (ER?) are described herein. The described invention also includes compositions and medicaments containing the aminopyridine derivatives as well as processes for the preparation and use of such compounds, compositions and medicaments.

Abstract: In the case of the materials according to the invention, the charge carrier mobility in the correspondingly prepared films is achieved if the molecules are composed in such a way that side chains—consisting of conjugated aromatic or heteroaromatic systems—are attached in direct conjugation to a central aromatic or heteroaromatic ring so that the total molecule acquires an octupolar structure. This octupolar structure permits an effective ?-? interaction of the molecules with one another in a manner such that stacking of a plurality of molecules along an imaginary axis (central ring) can take place and various stacks from among these stacks can interact with one another by intermeshing of the side chains. The electronic properties of the materials are determined both by the arrangement of the molecules in a layer and by the molecular design.

Abstract: The compounds of the present invention are of formula I: wherein A, R3, R4 is as defined herein, are useful as ligands for nicotinic receptors.

Abstract: ?- and ?-amino acid hydroxyethylamino sulfonyl urea derivative compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Abstract: The invention relates to novel dihydropyridinone derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

Abstract: The present invention relates to compounds of the formula wherein X and R1 to R8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.

Abstract: A zinc(II) complex which is lowly toxic, has high insulin-like activity, and is effectively usable as a hypoglycemic agent for the prevention or treatment of diabetes; a hypoglycemic agent containing the complex; a medicinal preparation which contains the complex and is useful as a preventive/remedy for diabetes; and a food containing the complex, such as a health food or supplementary health food. The hypoglycemic agent contains an organic zinc(II) complex having as a ligand a compound selected among aminoalkylpyridines, bis-optically active amino acids, bisaminoalkylcarboxylic acids, oligopeptides, oligopseudopeptides, di-substituted aminocarboxylic acids, ?- and ?-hydroxycarboxylic acids, vitamins, glutamine derivatives, etc.

Abstract: The present invention relates to novel CD40:CD154 binding interrupter compounds and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are capable of specifically binding CD154 and interrupting CD40:CD154 interaction.